Zions Bancorporation heads into its July 20 earnings date with analyst targets rising sharply but short positions quietly rebuilding — a split signal that makes this week's setup more interesting than the calm 1% weekly gain suggests.
The most striking development this week came from the Street. Both JP Morgan and Morgan Stanley lifted their price targets within 48 hours of each other. JP Morgan's Anthony Elian raised his target from $67 to $75 on July 1 while holding a Neutral rating. Morgan Stanley's Manan Gosalia went further, lifting to $77 from $68 while maintaining Overweight. These are the two clearest signals that institutional confidence in the Q2 setup is building. The mean consensus target now sits at $70.90, roughly in line with the current price of $69.19 — so the Street isn't pricing in heroics, but the direction of travel is clearly upward. Baird countered this slightly by downgrading from Outperform to Neutral on June 23, keeping its $68 target unchanged. That makes the analyst picture mixed but tilted toward cautious optimism: bulls point to improving loan and deposit growth, while bears flag slowing net interest income and capital ratio pressures as real risks heading into the back half of the year.
Short positioning tells a more complicated story. At 4.8% of free float, short interest is not extreme — but the month-on-month jump of 63% is hard to ignore. From roughly 4.4 million shares short in early June to 7.1 million now, the rebuild in borrowed positions has been sharp and sustained. The official FINRA fortnightly figure confirms the trend, showing 6.9 million shares short with a days-to-cover of 4.1 — above average for a regional bank. The borrow cost jumped more than 220% on the week to just under 0.50%, though in absolute terms it remains low and well within normal territory for a large-cap name. Availability is extremely loose at 6,269% — there are roughly 144 million shares available to borrow against 7 million currently borrowed — so there is no squeeze dynamic here. The short rebuild looks conviction-driven, not technically forced.
Options positioning is leaning constructively. The put/call ratio has dropped to 0.60, well below its 20-day average of 0.69 and more than one standard deviation below the mean. That shift away from hedging has been consistent over the past two weeks: the PCR was running near 0.78 in early June and has compressed steadily since. It suggests options traders are not bracing defensively ahead of July 20. The short score of 40.7 sits in the lower half of the range, consistent with this picture — short positioning is present but not threatening.
One institutional detail worth flagging: Two Sigma added over 1 million shares in the last reported quarter, and Wellington Management added 776,000. Fuller & Thaler also added 307,000. These are meaningful additions from active managers who don't typically hold regional banks as passive index overflow. On the inside, Chairman and CEO Harris Simmons purchased 4,500 shares at $59.03 back in February — the only buy in a run of small executive sells. That February purchase looks prescient given the stock has rallied roughly 17% since. The recent insider sells are all small and routine in character.
The earnings history here is unambiguously soft on the reaction side: the last two prints both saw the stock fall on the day, down 2.1% after Q1 2026 results in May and down 1.1% after the April report. Five-day reactions were similarly muted and negative. The question heading into July 20 is whether the combination of rising analyst targets, a constructive options skew, and a 10% one-month rally sets a higher bar — or whether the Street's target upgrades reflect genuine estimate revision momentum that earnings can confirm.
Watch whether the short rebuild continues through the two weeks before the print. If borrowed shares push above 8 million while analyst targets keep climbing, that divergence will be the sharpest tension in the setup.
See the live data behind this article on ORTEX.
Open ZION on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
